Neo has posted good revenue growth and the EPS has grown by around 50%.

Accompanied by a bullish golden crossover, I am waiting for a good breakout at the current consolidation for it to hit targets of 22/28/40
CMP 15.29

Technicals:
Bounce: Dipped below the 21-EMA Jul 27–28, then reclaimed it Jul 29 on 4.2× avg volume (6.0M shares) after Q2 results; follow-through Jul 30 on 2.3×.
Coming out of a triangle pattern.
YoY EPS growth (Q2 2026): +67% (adj. $0.05 vs $0.03); revenue +11% to $201.7M, beat guidance.
Catalyst: Q2 beat on Jul 28 with FY26 guidance raised (adj. EBITDA to $56–58M); adj. gross margin +260 bps YoY; NGS revenue +26%.
Tailwinds:

Oncology diagnostics demand + 12% average-unit-price gains showing pricing power
NGS testing secular growth (+26% YoY) taking share of clinical mix
Margin-expansion story just inflecting into consistent profitability
Rationale: A clean textbook entry — pre-earnings shakeout to the 21-EMA, then an emphatic high-volume reclaim on a beat-and-raise quarter. Earnings turn (breakeven → growing profits) plus raised guidance gives fundamental fuel, and the stock is consolidating just under its post-earnings high rather than fading. Risk is definable against the 21-EMA at $14.19.